← 返回

通过巨噬细胞来源的外泌体 miRNAs 靶向癌症:对肿瘤进展和耐药性的意义

英文原题:Targeting cancer via macrophage-derived exosomal miRNAs: implications for tumor progression and resistance.

查看英文原题

Targeting cancer via macrophage-derived exosomal miRNAs: implications for tumor progression and resistance.

PubMed 2025/11/20(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

近期关于巨噬细胞的研究表明,其通过影响局部肿瘤微环境和癌细胞,对肿瘤发生、进展、转移和化疗耐药作出贡献。外泌体构成细胞外囊泡的一个亚群,在癌细胞与巨噬细胞之间的相互作用中发挥了重要作用。本综述旨在讨论现有文献中关于利用巨噬细胞来源外泌体作为microRNA(miRNA)递送载体在肿瘤学应用中的研究。它将通过阐明药物和放射耐药等问题,评估这一治疗方法的分子原理及其增强癌症治疗的能力。本综述独特地强调了巨噬细胞来源外泌体miRNA的诊断和治疗潜力,总结了当前对其分子过程、肿瘤特异性以及克服治疗耐药策略的理解。本综述综合了近期研究,并评估了巨噬细胞来源外泌体及其miRNA如何参与癌症。这些囊泡是多用途工具,能够调节肿瘤行为,因为它们可以通过转录后调节和蛋白质磷酸化来调控肿瘤。此类经过工程改造的外泌体可能引入新的维度,因为它们能够递送靶向致癌或抑癌miRNA,以克服当前癌症治疗的局限性,尤其是药物和放射耐药。

因此,工程化巨噬细胞来源外泌体可能具有作为癌症治疗和克服治疗耐药新方法的潜力。

展开英文摘要原文

Recent studies on macrophages showed their contribution to tumorigenesis, progression, metastasis, and chemoresistance by influencing the local tumor microenvironment and cancer cells. Exosomes form a subset of extracellular vesicles and have played a major role in the interaction between cancer cells and macrophages. This review intends to discuss the existing literature on employing macrophage-derived exosomes as a vehicle for microRNA (miRNA) delivery in oncological applications. It will evaluate the molecular principles of this therapeutic approach and its capacity to enhance cancer therapy by elucidating problems like drug and radio-resistance. This review uniquely emphasizes the diagnostic and therapeutic potential of macrophage-derived exosomal miRNAs, summarizing current understandings into their molecular processes, tumor specificity, and strategies to overcome therapeutic resistance.

This review synthesizes recent studies and evaluates how macrophage-derived exosomes and their miRNAs contribute to cancers. These vesicles are multipurpose tools that regulate tumor behavior, considering they can regulate it through post-transcriptional regulation and protein phosphorylation.

Such exosomes that are engineered can potentially introduce a novel dimension because they have the capability of delivering targeted oncogenic or tumor-suppressive miRNAs to overcome limitations of current cancer therapeutics, particularly drug and radioresistance. Engineered macrophage-derived exosomes may thus have the potential as a novel approach for cancer treatment and overcoming therapeutic resistance.

论文信息

作者
Ramalingam PS、Afzal M、Babu MA、M M R、Sahoo S、Pandey SN、Ali H、Hussain MS
单位
Protein Engineering Lab, School of Biosciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.India
文献类型
综述
期刊
Frontiers in immunology2025
原文标识
PubMed 41357196 · DOI 10.3389/fimmu.2025.1683799